Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ ALK-rearranged non-small cell lung cancer

Discusses risks and benefits of adjuvant therapy for treatment of earlier stage and locoregional lung cancer; advocates genome sequencing of earlier stage lung cancer. READ ARTICLE

Translational Lung Cancer Research DOI: 33569340

Authors: Reyes, Roxana, Reguart, Noemi

Real-World OutcomesKirk SmithJanuary 1, 2021Early stage, neoadjuvant therapy, targeted therapy, ALK, EGFR, NSCLC